drugset / Trial / NCT05607563
A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours
Non-randomizedSequentialOpen-labelTreatment
Summary
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PM1009 for patients with advanced tumors, also to explore the recommended Phase Ⅱ Dose（RP2D） of PM1009. PM1009 is a new novel fully human anti-TIGIT x PVRIG bispecific antibody, containing a wildtype IgG1 Fc and has high monovalent affinity to each target, it can binds to both TIGIT and PVRIG overexpressing target cells and binds to TIGIT and PVRIG simultaneously.
Timeline
- Start
- 2022-11-21
- Primary completion
- 2023-11
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PM1009 | Unknown | 120 mg | Intravenous |
| Subject | PM1009 | Unknown | 300 mg | Intravenous |
| Subject | PM1009 | Unknown | 600 mg | Intravenous |
| Subject | PM1009 | Unknown | 1200 mg | Intravenous |
Indications
No indication recorded.